Maternal Immunization and Antenatal Care Situation Analysis Report of the MIACSA project 2016–2019

Overview

Vaccine-preventable diseases are among the main causes of global child morbidity and mortality, particularly in low- and middle-income countries (LMICs). Maternal vaccines given to pregnant women in the second or third trimester have emerged as a promising way to address vaccine-preventable diseases, providing protection to the newborn during the most vulnerable period in life, through the trans-placental transfer of maternal antibodies.

A multi-method study, the Maternal Immunization and Antenatal Care Situation Analysis (MIACSA), was conducted between November 2016 and June 2019 (32 months) aiming to explore current and future preparedness to introduce and implement new maternal vaccines. 

The project aimed to develop a typology of health systems in terms of how they are delivering vaccinesto pregnant women, to understand what system attributes correlate with high performance in the delivery of vaccines to pregnant women, and to assess the path forward for introducing additional vaccines for pregnant women.